Navidea announces interim analysis for Phase III Lymphoseek trial

01/6/2013 | Business Wire

Navidea Biopharmaceuticals said it has gathered a sufficient number of participants in its NEO3-06 Phase III trial to do a pre-planned interim analysis of Lymphoseek in patients with head and neck cancer. The analysis will compare the pathological findings on sentinel lymph nodes identified using Lymphoseek with those of lymph nodes removed in a full nodal dissection surgery of the head and neck. Findings from the analysis are expected later this year.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Customer Service Director
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
Minneapolis, MN
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID